Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats

PLoS One. 2014 Sep 8;9(9):e106849. doi: 10.1371/journal.pone.0106849. eCollection 2014.

Abstract

Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic changes upon FF treatment of fructose fed rats. Three groups with 6 animals each were defined as control, fructose-fed and fructose-fed/FF treated. Male Wistar Unilever Rats were subjected to 10% fructose-feeding for 20 days. On day 14, fenofibrate treatment (100 mg/kg p.o.) was initiated and maintained for 7 days. Lipid species in serum were analyzed using mass spectrometry (ESI-MS/MS; LC-FT-MS, GC-MS) on days 0, 14 and 20 in all three groups. In addition, lipid levels in liver and intestine were determined. Short-chain TAGs increased in serum and liver upon fructose-feeding, while almost all TAG-species decreased under FF treatment. Long-chain unsaturated DAG-levels (36:1, 36:2, 36:4, 38:3, 38:4, 38:5) increased upon FF treatment in rat liver and decreased in rat serum. FAs, especially short-chain FAs (12:0, 14:0, 16:0) increased during fructose-challenge. VLDL secretion increased upon fructose-feeding and together with FA-levels decreased to control levels during FF treatment. Fructose challenge of de novo fatty acid synthesis through fatty acid synthase (FAS) may enhance the release of FAs ≤ 16:0 chain length, a process reversed by FF-mediated PPARα-activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diglycerides / blood*
  • Fatty Acids / blood*
  • Fenofibrate / administration & dosage*
  • Fructose / administration & dosage*
  • Male
  • Rats
  • Rats, Wistar
  • Triglycerides / blood*

Substances

  • Diglycerides
  • Fatty Acids
  • Triglycerides
  • Fructose
  • Fenofibrate

Grants and funding

This work was supported by the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement n° 202272, IP-Project LipidomicNet and BMBF (“SysMBo,” sponsorship number 0315494C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.